NEW YORK–(EMWNews)–Clinilabs, Inc., a specialty contract research organization (CRO), has

completed expansion of its Phase I unit. This expansion brings the

Company’s Phase I facility to 68-beds, which

includes two new large observation rooms that can accommodate up to four

beds each, or up to 12 PK seats.

The Company conducts Phase I studies in any therapeutic area, including

pharmacokinetic (PK), pharmacodynamic (PD), bioavailability (BA),

bioequivalence (BE), drug interaction, and food interaction studies.

Additionally, Clinilabs offers specialty services for complex PD

studies, such as those that involve the collection of mood, cognition,

psychomotor functioning, EEG, quantitative EEG, evoked potential (EP),

and imaging data.

“Phase I studies are becoming increasingly

complex and sponsors depend on data from these studies to make crucial

decisions about their development programs,”

stated Dr. Gary Zammit, President and CEO of Clinilabs. “Clinilabs’

state-of-the-art facility is an ideal location for pharmaceutical and

biotechnology companies looking for outstanding service for their Phase

I studies,” he added.

Conveniently located in New York City, Clinilabs can recruit patients

from a large and diverse population, including healthy adult, healthy

elderly, Japanese, Chinese, and key patient populations. In addition,

Clinilabs’ metropolitan location provides

sponsors, as well as patients, with easy access to transportation hubs

and major subway and bus lines.

Clinilabs Phase I facility is staffed with highly qualified physicians,

nurses, and research associates, providing service 24 hours a day, 7

days a week.

About Clinilabs, Inc.

Clinilabs is a specialty contract research organization (CRO) that

provides a full portfolio of services to pharmaceutical, biotechnology,

and medical device companies involved in the development of central

nervous system (CNS) and cardiovascular (CV) therapeutics. The Company

also provides early phase services in a wider range of therapeutic areas

at its Phase I facility. Established in 2001, Clinilabs has provided

services to more than one third of the world’s

top 20 pharmaceutical companies, and has been involved in 7 successful

New Drug Applications (NDAs) in central nervous system (CNS) and

cardiovascular (CV) indications. For more information, please visit www.clinilabs.com.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions